drugset
drugset / Trial / NCT04763928

Trial in AML Secondary to MPNs Patients, Unfit for Intensive Chemotherapy, Investigating a Treatment Combination Including Decitabine and Venetoclax

NCT04763928 ↗

Phase 2 Active not recruiting 101 enrolled GIMEMA Foundation
NaSingle-groupOpen-labelTreatment

Summary

Prospective, multi-center, intervention, open clinical trial for the treatment of AML secondary to MPN in patients unfit for intensive chemotherapy investigating a combination regimen including VEN and DEC.

Timeline

Start
2021-12-03
Primary completion
2024-10-25
Completion
2026-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Decitabine Small molecule 20 mg/m2 Intravenous
Subject Venetoclax Small molecule 400 mg Oral

Indications

acute myeloid leukemia